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•  Retrospective chart review of 151 women with severe PreE who 
delivered at Lehigh Valley Health Network from 2009 to 2010. 
•  Six societies with aspirin-use guidelines were identified and a list 
of criteria for each guideline was established. 
•  Each subject’s records were reviewed using Epic, EHMR, and 
CPO to identify presence or absence of specific criteria from each 
guideline. 
•  The proportion of subjects with pre-existing increased risk for 
preeclampsia per each guideline was calculated along with the 
overall frequencies of individual risk factors present in the cohort. 
•  Published risk reduction rates for were applied to estimate the 
theoretic impact on preeclampsia, IUGR, and preterm birth with 
adherence to society guidelines within this cohort.                                      





Variation between aspirin prophylaxis guidelines is significant. While the 
SOGC 2014 criteria identified the greatest proportion of the study cohort 
as being at risk during retrospective application of 32 criteria, use in the 
clinical setting is not practical and may not identify patients early enough 
for effective aspirin intervention. Other guidelines in current use would 
identify <50% of pregnancies that might have benefited from aspirin 
prophylaxis, which highlights the importance of optimizing screening 
efforts. Improved and more consistent screening recommendations 
across guidelines would simplify decisions about aspirin prophylaxis 
and reduce variation in use. This would in turn maximize reduction of 
preeclampsia related morbidity and mortality, including IUGR and preterm 
birth. Thus a need exists for a consensus on criteria for preeclampsia risk 
stratification as well as better tools for screening. 
Conclusions
•  Preeclampsia (PreE) is a hypertensive disease of pregnancy, 
which occurs in 4.6% of pregnancies and accounts for 50-60,000 
maternal deaths worldwide annually. 
•  PreE leads to increased risk of developing cardiovascular disease 
in mothers and increased intrauterine growth restriction (IUGR) 
and prematurity in neonates. 
•  The use of aspirin in pregnant women at increased risk for 
preeclampsia can decrease incidence of PreE, IUGR, and preterm 
birth by up to 24%, 20%, and 14% respectively.
•  Several clinical practice guidelines exist to identify women who 
would benefit from aspirin prophylaxis, however, there is great 
variation in the eligibility criteria used by each guideline. 
•  Six such guidelines are from ACOG, USPSTF, WHO, SOGC, NICE-
PRECOG, and ESC. 
•  This study aims to identify the variations between these clinical 
practice guidelines and determine their theoretical impact on 
prevention of potential PreE, IUGR and preterm birth in a cohort of 
pregnancies that were complicated by severe PreE.      
 
Problem Statement
Several professional societies have proposed guidelines for 
prophylactic Aspirin use in the prevention of preeclampsia, however 
there is great variability between their recommendations and the 
impact of this variability on clinical care and outcomes has not been 
assessed.
Table 1. Frequency of Preeclampsia Risk Factors from Society Guideliens Presentin Study Cohort













History of early onset preeclampsia and preterm delivery at less than 34 0/7 weeks of 
gestation X      4%
Preeclampsia in more than one prior pregnancy X      0%
History of preeclampsia, especially when accompanied by an adverse outcome  X     7.30%
History of previous preeclampsia   X X   7.30%
Family history of preeclampsia (Mother or sister)   +   + + 7.30%
Hypertensive disease in a previous pregnancy      X X 11.30%
Multifetal gestation  X X X + + 12%
Chronic hypertension  X X X X X 9.30%
Type one or Type two DM  X X X X X 4%
Renal disease  X X X X X 0.66%
Autoimmune disease (SLE or Antiphospholipis Syndrome)   X X  X X 2%
Antiphospholipid Syndrome    X   1.30%
Nulliparity  +  + +  67.50%
First Pregnancy      + 50.00%
Obesity (BMI >30 kg/m2)  +  +   35.76%
BMI > 35 kg/m2 or more at first visit      + + 21.85%
Sociodemographic characteristics (African American, low socioeconomic status)  +     45.70%
Age > 35  +     16.60%
Age > 40    + + + 5.30%
Personal history factors (low maternal birth weight or small for gestational age, previous 
adverse pregnancy outcome)  +     0%
Greater than 10 year pregnancy interval   +   + + 8%
Overweight (BMI 25-29)    +   18%
Low maternal birth weight and/or preterm delivery    +   0%
Proteinuria at first antenatal visit     X   14.60%
Family history of early onset cardiovascular disease    +   8.00%
Heritable thrombophilia (Factor V Leiden, Protein S deficiency)    +   1.30%
Increased pre-pregnancy trilycerides    +   0%
Non-smoking + 85.40%
Cocaine & Methamphetamine use + 0.66%
Previous miscarriage at < 10 weeks with the same partner + 0%
New partner + 1.30%
Short duration of sexual relationship with current partner + 0%
Reproductive technologies + 6.60%
First antenatal visit SBP > 130 or DBP > 80 + 29%
Vaginal bleeding in early pregnancy + 8.60%
Gestational trophoblastic disease + 0%
Abnormal PAPP or free Beta hCG in the 1st trimester + 6%
Gestational Hypertension + 26.50%
Abnormal AFP, hCG, inhibin A, E3 + 16%
Excessive weight gain in pregnancy + 34%
Abnormal uterine artery doppler + 4.60%
IUGR + 20.50%
Infection during pregnancy (e.g., UTI, peridontal disease) + 24.50%
Investigational lab markers (1st trimester: PAPP-A, PIGF, PP-13; 2nd Trimester: SFL+- 1/
PIGF, PA-1/2, vWF, Leptin) + 6%
Table 2. Percentages of Study Cohort that Meet Individual Guideline Criteria for Aspirin Prophylaxis and 













Percentage of cohort meeting 4 43 30 97 46 40 
Estimated cases preeclampsia prevented* 9.24 103 72.6 233 110.88 96.36
Esimated cases IUGR prevented* 2.64 15.84 11.88 40.92 15.84 13.2
Estimated cases preterm birth prevented* 4.62 50.82 37 96.36 50.16 43.56
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X- Single risk factor indicatinguse of prophylaactic aspirin
+- Moderate risk factor - presence of two or more indicates use of prophylactic aspirin
* Cases prevented per 1000
Aspirin prevention efficacy estimates for preeclampsia (24%), intrauterine growth restriction (20%) and preterm birth (14%)
